• Home
  • Dabrafenib 75mg
  • Dabrafenib 75mg

Dabrafenib 75mg

52120

Dabrafenib is used with trametinib for melanoma with a BRAF V600 mutation that cannot be removed by surgery or has spread.

It is also used with trametinib after surgery for BRAF V600 mutation-positive melanoma to lower the chance of the cancer coming back.

Dabrafenib with trametinib is used for several BRAF V600E mutation-positive cancers, including metastatic non-small cell lung cancer, anaplastic thyroid cancer, some solid tumours, and some low-grade gliomas.

Usual adult dose range: 50mg to 150mg twice daily; the usual starting dose is 150mg twice daily, often with trametinib when the treatment plan calls for combination therapy.

Indications vary by country and change over time; this website contains information for general patient information and should be checked against local prescribing information before clinical use.

Verification Approach: Each indication and usual dose-range sentence was drafted from at least two recognised medicines information sources, usually FDA/DailyMed or an FDA label plus EMA/eMC, MedlinePlus, Mayo Clinic, Cancer Research UK, NCI/ Cancer.gov, or another reputable medicines-information source. Doses are general adult/patient-information ranges and must not be used to prescribe or change treatment.
  • FDA/DailyMed prescribing information and FDA Oncology/Hematology approval notifications.
  • EMA and UK eMC Summary of Product
    Characteristics and patient leaflets where available.
  • NCI Cancer Drug Information/Cancer.gov and Cancer Research UK medicine information where available.
  • MedlinePlus, NHS/NICE, and other national medicines information for non-oncology or immune/respiratory medicines.
  • Peer-reviewed FDA approval summaries or manufacturer regulatory notices for very new, withdrawn, or region-specific
    indications.